Copyright Reports & Markets. All rights reserved.

Global Angiotensin II Receptor Blocker (ARBs) API Market Growth (Status and Outlook) 2021-2026

Request for Sample of this report
Buy now

1 Scope of the Report

  • 1.1 Market Introduction
  • 1.2 Years Considered
  • 1.3 Research Objectives
  • 1.4 Market Research Methodology
  • 1.5 Research Process and Data Source
  • 1.6 Economic Indicators
  • 1.7 Currency Considered

2 Executive Summary

  • 2.1 World Market Overview
    • 2.1.1 Global Angiotensin II Receptor Blocker (ARBs) API Market Size 2016-2026
    • 2.1.2 Angiotensin II Receptor Blocker (ARBs) API Market Size CAGR by Region 2020 VS 2021 VS 2026
  • 2.2 Angiotensin II Receptor Blocker (ARBs) API Segment by Type
    • 2.2.1 Valsartan
    • 2.2.2 Valsartan
    • 2.2.3 Telmisartan
    • 2.2.4 Losartan
    • 2.2.5 Candesartan
    • 2.2.6 Olmesartan
    • 2.2.7 Others
  • 2.3 Angiotensin II Receptor Blocker (ARBs) API Market Size by Type
    • 2.3.1 Global Angiotensin II Receptor Blocker (ARBs) API Market Size CAGR by Type
    • 2.3.2 Global Angiotensin II Receptor Blocker (ARBs) API Market Size Market Share by Type (2016-2021)
  • 2.4 Angiotensin II Receptor Blocker (ARBs) API Segment by Application
    • 2.4.1 Essential Hypertension
    • 2.4.2 Secondary Hypertension
  • 2.5 Angiotensin II Receptor Blocker (ARBs) API Market Size by Application
    • 2.5.1 Global Angiotensin II Receptor Blocker (ARBs) API Market Size CAGR by Application
    • 2.5.2 Global Angiotensin II Receptor Blocker (ARBs) API Market Size Market Share by Application (2016-2021)

3 Angiotensin II Receptor Blocker (ARBs) API Market Size by Players

  • 3.1 Angiotensin II Receptor Blocker (ARBs) API Market Size Market Share by Players
    • 3.1.1 Global Angiotensin II Receptor Blocker (ARBs) API Revenue by Players (2019-2021E)
    • 3.1.2 Global Angiotensin II Receptor Blocker (ARBs) API Revenue Market Share by Players (2019-2021E)
  • 3.2 Global Angiotensin II Receptor Blocker (ARBs) API Key Players Head office and Products Offered
  • 3.3 Market Concentration Rate Analysis
    • 3.3.1 Competition Landscape Analysis
    • 3.3.2 Concentration Ratio (CR3, CR5 and CR10) (2019-2021E)
  • 3.4 New Products and Potential Entrants
  • 3.5 Mergers & Acquisitions, Expansion

4 Angiotensin II Receptor Blocker (ARBs) API by Regions

  • 4.1 Angiotensin II Receptor Blocker (ARBs) API Market Size by Regions (2016-2021)
  • 4.2 Americas Angiotensin II Receptor Blocker (ARBs) API Market Size Growth (2016-2021)
  • 4.3 APAC Angiotensin II Receptor Blocker (ARBs) API Market Size Growth (2016-2021)
  • 4.4 Europe Angiotensin II Receptor Blocker (ARBs) API Market Size Growth (2016-2021)
  • 4.5 Middle East & Africa Angiotensin II Receptor Blocker (ARBs) API Market Size Growth (2016-2021)

5 Americas

  • 5.1 Americas Angiotensin II Receptor Blocker (ARBs) API Market Size by Country (2016-2021)
  • 5.2 Americas Angiotensin II Receptor Blocker (ARBs) API Market Size by Type (2016-2021)
  • 5.3 Americas Angiotensin II Receptor Blocker (ARBs) API Market Size by Application (2016-2021)
  • 5.4 United States
  • 5.5 Canada
  • 5.6 Mexico
  • 5.7 Brazil

6 APAC

  • 6.1 APAC Angiotensin II Receptor Blocker (ARBs) API Market Size by Region (2016-2021)
  • 6.2 APAC Angiotensin II Receptor Blocker (ARBs) API Market Size by Type (2016-2021)
  • 6.3 APAC Angiotensin II Receptor Blocker (ARBs) API Market Size by Application (2016-2021)
  • 6.4 China
  • 6.5 Japan
  • 6.6 Korea
  • 6.7 Southeast Asia
  • 6.8 India
  • 6.9 Australia

7 Europe

  • 7.1 Europe Angiotensin II Receptor Blocker (ARBs) API by Country (2016-2021)
  • 7.2 Europe Angiotensin II Receptor Blocker (ARBs) API Market Size by Type (2016-2021)
  • 7.3 Europe Angiotensin II Receptor Blocker (ARBs) API Market Size by Application (2016-2021)
  • 7.4 Germany
  • 7.5 France
  • 7.6 UK
  • 7.7 Italy
  • 7.8 Russia

8 Middle East & Africa

  • 8.1 Middle East & Africa Angiotensin II Receptor Blocker (ARBs) API by Region (2016-2021)
  • 8.2 Middle East & Africa Angiotensin II Receptor Blocker (ARBs) API Market Size by Type (2016-2021)
  • 8.3 Middle East & Africa Angiotensin II Receptor Blocker (ARBs) API Market Size by Application (2016-2021)
  • 8.4 Egypt
  • 8.5 South Africa
  • 8.6 Israel
  • 8.7 Turkey
  • 8.8 GCC Countries

9 Market Drivers, Challenges and Trends

  • 9.1 Market Drivers and Impact
    • 9.1.1 Growing Demand from Key Regions
    • 9.1.2 Growing Demand from Key Applications and Potential Industries
  • 9.2 Market Challenges and Impact
  • 9.3 Market Trends

10 Global Angiotensin II Receptor Blocker (ARBs) API Market Forecast

  • 10.1 Global Angiotensin II Receptor Blocker (ARBs) API Forecast by Regions (2021-2026)
    • 10.1.1 Global Angiotensin II Receptor Blocker (ARBs) API Forecast by Regions (2021-2026)
    • 10.1.2 Americas Angiotensin II Receptor Blocker (ARBs) API Forecast
    • 10.1.3 APAC Angiotensin II Receptor Blocker (ARBs) API Forecast
    • 10.1.4 Europe Angiotensin II Receptor Blocker (ARBs) API Forecast
    • 10.1.5 Middle East & Africa Angiotensin II Receptor Blocker (ARBs) API Forecast
  • 10.2 Americas Angiotensin II Receptor Blocker (ARBs) API Forecast by Countries (2021-2026)
    • 10.2.1 United States Angiotensin II Receptor Blocker (ARBs) API Market Forecast
    • 10.2.2 Canada Angiotensin II Receptor Blocker (ARBs) API Market Forecast
    • 10.2.3 Mexico Angiotensin II Receptor Blocker (ARBs) API Market Forecast
    • 10.2.4 Brazil Angiotensin II Receptor Blocker (ARBs) API Market Forecast
  • 10.3 APAC Angiotensin II Receptor Blocker (ARBs) API Forecast by Region (2021-2026)
    • 10.3.1 China Angiotensin II Receptor Blocker (ARBs) API Market Forecast
    • 10.3.2 Japan Angiotensin II Receptor Blocker (ARBs) API Market Forecast
    • 10.3.3 Korea Angiotensin II Receptor Blocker (ARBs) API Market Forecast
    • 10.3.4 Southeast Asia Angiotensin II Receptor Blocker (ARBs) API Market Forecast
    • 10.3.5 India Angiotensin II Receptor Blocker (ARBs) API Market Forecast
    • 10.3.6 Australia Angiotensin II Receptor Blocker (ARBs) API Market Forecast
  • 10.4 Europe Angiotensin II Receptor Blocker (ARBs) API Forecast by Country (2021-2026)
    • 10.4.1 Germany Angiotensin II Receptor Blocker (ARBs) API Market Forecast
    • 10.4.2 France Angiotensin II Receptor Blocker (ARBs) API Market Forecast
    • 10.4.3 UK Angiotensin II Receptor Blocker (ARBs) API Market Forecast
    • 10.4.4 Italy Angiotensin II Receptor Blocker (ARBs) API Market Forecast
    • 10.4.5 Russia Angiotensin II Receptor Blocker (ARBs) API Market Forecast
  • 10.5 Middle East & Africa Angiotensin II Receptor Blocker (ARBs) API Forecast by Region (2021-2026)
    • 10.5.1 Egypt Angiotensin II Receptor Blocker (ARBs) API Market Forecast
    • 10.5.2 South Africa Angiotensin II Receptor Blocker (ARBs) API Market Forecast
    • 10.5.3 Israel Angiotensin II Receptor Blocker (ARBs) API Market Forecast
    • 10.5.4 Turkey Angiotensin II Receptor Blocker (ARBs) API Market Forecast
    • 10.5.5 GCC Countries Angiotensin II Receptor Blocker (ARBs) API Market Forecast
  • 10.6 Global Angiotensin II Receptor Blocker (ARBs) API Forecast by Type (2021-2026)
  • 10.7 Global Angiotensin II Receptor Blocker (ARBs) API Forecast by Application (2021-2026)

11 Key Players Analysis

  • 11.1 Teva Pharmaceutical
    • 11.1.1 Teva Pharmaceutical Company Information
    • 11.1.2 Teva Pharmaceutical Angiotensin II Receptor Blocker (ARBs) API Product Offered
    • 11.1.3 Teva Pharmaceutical Angiotensin II Receptor Blocker (ARBs) API Revenue, Gross Margin and Market Share (2019-2021)
    • 11.1.4 Teva Pharmaceutical Main Business Overview
    • 11.1.5 Teva Pharmaceutical Latest Developments
  • 11.2 Aurobindo Pharma
    • 11.2.1 Aurobindo Pharma Company Information
    • 11.2.2 Aurobindo Pharma Angiotensin II Receptor Blocker (ARBs) API Product Offered
    • 11.2.3 Aurobindo Pharma Angiotensin II Receptor Blocker (ARBs) API Revenue, Gross Margin and Market Share (2019-2021)
    • 11.2.4 Aurobindo Pharma Main Business Overview
    • 11.2.5 Aurobindo Pharma Latest Developments
  • 11.3 Viatris
    • 11.3.1 Viatris Company Information
    • 11.3.2 Viatris Angiotensin II Receptor Blocker (ARBs) API Product Offered
    • 11.3.3 Viatris Angiotensin II Receptor Blocker (ARBs) API Revenue, Gross Margin and Market Share (2019-2021)
    • 11.3.4 Viatris Main Business Overview
    • 11.3.5 Viatris Latest Developments
  • 11.4 Tianyu Pharma
    • 11.4.1 Tianyu Pharma Company Information
    • 11.4.2 Tianyu Pharma Angiotensin II Receptor Blocker (ARBs) API Product Offered
    • 11.4.3 Tianyu Pharma Angiotensin II Receptor Blocker (ARBs) API Revenue, Gross Margin and Market Share (2019-2021)
    • 11.4.4 Tianyu Pharma Main Business Overview
    • 11.4.5 Tianyu Pharma Latest Developments
  • 11.5 Huahai Pharmaceutical
    • 11.5.1 Huahai Pharmaceutical Company Information
    • 11.5.2 Huahai Pharmaceutical Angiotensin II Receptor Blocker (ARBs) API Product Offered
    • 11.5.3 Huahai Pharmaceutical Angiotensin II Receptor Blocker (ARBs) API Revenue, Gross Margin and Market Share (2019-2021)
    • 11.5.4 Huahai Pharmaceutical Main Business Overview
    • 11.5.5 Huahai Pharmaceutical Latest Developments
  • 11.6 Menovo
    • 11.6.1 Menovo Company Information
    • 11.6.2 Menovo Angiotensin II Receptor Blocker (ARBs) API Product Offered
    • 11.6.3 Menovo Angiotensin II Receptor Blocker (ARBs) API Revenue, Gross Margin and Market Share (2019-2021)
    • 11.6.4 Menovo Main Business Overview
    • 11.6.5 Menovo Latest Developments
  • 11.7 Rundu Pharma
    • 11.7.1 Rundu Pharma Company Information
    • 11.7.2 Rundu Pharma Angiotensin II Receptor Blocker (ARBs) API Product Offered
    • 11.7.3 Rundu Pharma Angiotensin II Receptor Blocker (ARBs) API Revenue, Gross Margin and Market Share (2019-2021)
    • 11.7.4 Rundu Pharma Main Business Overview
    • 11.7.5 Rundu Pharma Latest Developments
  • 11.8 Kinglyuan Pharmaceutical
    • 11.8.1 Kinglyuan Pharmaceutical Company Information

…

According to this latest study, the 2021 growth of Angiotensin II Receptor Blocker (ARBs) API will have significant change from previous year. By the most conservative estimates of global Angiotensin II Receptor Blocker (ARBs) API market size (most likely outcome) will be a year-over-year revenue growth rate of XX% in 2021, from US$ xx million in 2020. Over the next five years the Angiotensin II Receptor Blocker (ARBs) API market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2026.

This report presents a comprehensive overview, market shares, and growth opportunities of Angiotensin II Receptor Blocker (ARBs) API market by product type, application, key players and key regions and countries.

Segmentation by type: breakdown data from 2016 to 2021 in Section 2.3; and forecast to 2026 in section 10.7.
Valsartan
Irbesartan
Telmisartan
Losartan
Candesartan
Olmesartan
Others

Segmentation by application: breakdown data from 2016 to 2021, in Section 2.4; and forecast to 2026 in section 10.8.
Essential Hypertension
Secondary Hypertension

This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The report also presents the market competition landscape and a corresponding detailed analysis of the major players in the market. The key players covered in this report: Breakdown data in in Chapter 3.
Teva Pharmaceutical
Aurobindo Pharma
Viatris
Tianyu Pharma
Huahai Pharmaceutical
Menovo
Rundu Pharma
Kinglyuan Pharmaceutical
Second Pharma
Apeloa
Jiangxi Synergy Pharmaceutical
Buy now